Capozide 50/25 Interactions
There are 618 drugs known to interact with Capozide 50/25 (captopril/hydrochlorothiazide), along with 18 disease interactions, and 3 alcohol/food interactions. Of the total drug interactions, 56 are major, 505 are moderate, and 57 are minor.
- View all 618 medications that may interact with Capozide 50/25
- View Capozide 50/25 alcohol/food interactions (3)
- View Capozide 50/25 disease interactions (18)
Most frequently checked interactions
View interaction reports for Capozide 50 / 25 (captopril / hydrochlorothiazide) and the medicines listed below.
Capozide 50/25 alcohol/food interactions
There are 3 alcohol/food interactions with Capozide 50 / 25 (captopril / hydrochlorothiazide).
Capozide 50/25 disease interactions
There are 18 disease interactions with Capozide 50 / 25 (captopril / hydrochlorothiazide) which include:
- angioedema
- bone marrow suppression
- hemodialysis
- hyperkalemia
- hypotension
- anuria
- electrolyte losses
- liver disease
- lupus erythematosus
- renal function disorders
- liver disease
- renal dysfunction
- asthma
- diabetes
- hyperlipidemia
- hyperparathyroidism
- hyperuricemia
- thyroid function tests
More about Capozide 50 / 25 (captopril / hydrochlorothiazide)
- Capozide 50/25 consumer information
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: ACE inhibitors with thiazides
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.